Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Vishee Medical Technology CoSHSE:688580 -0.98%91 Return-on-Tangible-Asset is 14.57% as of Mar. 2026, which is 11% above its 10-year median of 13.18. GuruFocus rates SHSE:688580 with a GF Score™ of 91/100 and a GF Value™ of ¥55.17 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Nanjing Vishee Medical Technology Co ranks better than 82.65% on this metric.
The historical rank and industry rank for Nanjing Vishee Medical Technology Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:688580'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6 Med: 13.18 Max: 29.61
Current: 10.14
During the past 13 years, Nanjing Vishee Medical Technology Co's highest Return-on-Tangible-Asset was 29.61%. The lowest was 6.00%. And the median was 13.18%.
SHSE:688580's Return-on-Tangible-Asset is ranked better than 82.65% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.76
vs SHSE:688580: 10.14
Nanjing Vishee Medical Technology Co (SHSE:688580) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Nanjing Vishee Medical Technology Co Return-on-Tangible-Asset Related Terms
Nanjing Vishee Medical Technology Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Vishee Medical Technology Co Return-on-Tangible-Asset Chart
SHSE:688580 vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Nanjing Vishee Medical Technology Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Vishee Medical Technology Co Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Vishee Medical Technology Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Nanjing Vishee Medical Technology Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 14.57% mean?
Nanjing Vishee Medical Technology Co (SHSE:688580) has a Return-on-Tangible-Asset of 14.57% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Nanjing Vishee Medical Technology Co and its competitors. This is 11% above median its historical median of 13.18. Over the past decade, Nanjing Vishee Medical Technology Co's Return-on-Tangible-Asset has ranged from 6.00 to 29.61. According to the industry distribution chart, Nanjing Vishee Medical Technology Co ranks #148 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 17.4%.
Is Nanjing Vishee Medical Technology Co's Return-on-Tangible-Asset too high?
Nanjing Vishee Medical Technology Co's current Return-on-Tangible-Asset of 14.57% is 11% above median its 10-year median of 13.18. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 29.61. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.76. Nanjing Vishee Medical Technology Co's value of 14.57% is 1817.1% above this industry median. Based on the distribution chart, Nanjing Vishee Medical Technology Co ranks #148 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nanjing Vishee Medical Technology Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Vishee Medical Technology Co's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nanjing Vishee Medical Technology Co ranks #148 out of 853 companies for Return-on-Tangible-Asset. This places Nanjing Vishee Medical Technology Co in the top 17% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.76. Nanjing Vishee Medical Technology Co's value of 14.57% is 1817.1% above this benchmark. Historically, Nanjing Vishee Medical Technology Co's own Return-on-Tangible-Asset has ranged from 6.00 to 29.61 over the past decade. While the company's 10-year median is 13.18 vs. the industry median of 0.76, Nanjing Vishee Medical Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.76, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Vishee Medical Technology Co's current Return-on-Tangible-Asset of 14.57% is 1817.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Nanjing Vishee Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Vishee Medical Technology Co's current Return-on-Tangible-Asset is 14.57%, which is 11% above median its own 10-year median of 13.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Vishee Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Vishee Medical Technology Co (SHSE:688580) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥55.17, compared to a current price of ¥49.76 — trading 9.8% below its estimated fair value. The current Return-on-Tangible-Asset is 14.57%, which is 11% above median its 10-year median of 13.18 and 1817.1% above the Medical Devices & Instruments industry median of 0.76. Nanjing Vishee Medical Technology Co's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Nanjing Vishee Medical Technology Co (SHSE:688580), the current Return-on-Tangible-Asset is 14.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Vishee Medical Technology Co (SHSE:688580) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Vishee Medical Technology Co stock appears to be undervalued.
The current stock price of ¥49.76 is trading 9.8% below its estimated GF Value™ of ¥55.17.
GuruFocus considers Nanjing Vishee Medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688580:
Return-on-Tangible-Asset: 14.57% (11% above median its 10-year median of 13.18)
GF Value™: ¥55.17 vs. price of ¥49.76 (9.8% below fair value)
Industry Position: 1817.1% above the Medical Devices & Instruments median (#148 of 853)
No single metric tells the full story. See the SHSE:688580 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanjing Vishee Medical Technology Co Ltd is engaged in production and sales of rehabilitation medical devices. The company's products under Pelvic floor and postpartum rehabilitation include Pelvic floor electromyography biofeedback instrument; Myotrac series biological stimulation feedback instrument; Ruiyi Series Biostimulation Feedback Apparatus; Magneuro Series Magnetic Stimulator; Female psychological rehabilitation; Neonatal electroencephalograph; Consumables; and under Mental rehabilitation include Multi-parameter biofeedback instrument; Group biofeedback; Magneuro Series Magnetic Stimulator; and Cognitive dysfunction treatment software.
91GF Score
Get the complete analysis for SHSE:688580
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688580 has been successfully added to your 
